BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.. The minimum follow-up duration of all patients is 6 months.
Outpatient Administration of High Dose BEAM Chemotherapy As. patients with Hodgkin's or non-Hodgkin's lymphoma that persists or recurs following standard
Lymphoma Hodgkin's Disease, Drug: Melphalan Drug: Ara-C Drug: VP-16 Drug:. Study of Rituxan in Patient Receiving BEAM Chemotherapy and Autologous .
lymphoma or Hodgkin's lymphoma who require additional therapy following standard chemotherapy. The aim is to either cure your disease, or lengthen.
High-dose BEAM chemotherapy with autologous peripheral blood. for unselected patients with primary refractory or relapsed Hodgkin's disease. . relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation.